Cybin, a life-sciences company focused on advancing psychedelic and nutraceutical-based products, today announced that its CEO, Doug Drysdale, is featured in an exclusive audio interview with NetworkNewsWire (“NNW”) – a financial news and content distribution company and one of 50+ brands in the InvestorBrandNetwork (“IBN”). During the interview, Drysdale provides insight into Cybin’s 2020 milestones, near-term goals and its efforts to build on the momentum of an industry that continues to ramp up. “We have secured a source of GMP psilocybin API to support our initial clinical program, and we’ve initiated a program to synthesize our own proprietary API to support future programs,” Drysdale said in the interview. “We’re also very busy on the business development front, and I fully anticipate that we’ll be announcing a number of transactions that potentially expand our development capabilities and add to our IP portfolio.”
To view the full press release, visit http://ibn.fm/iTu8B
About Cybin Corp.
Cybin is a life-sciences company advancing mushroom-based psychedelic pharmaceuticals and non-psychedelic nutraceutical products for diverse markets as potential therapies for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems aiming to improve bioavailability to achieve the desired effects of psychedelics at low-dosage levels. The new delivery systems will be studied through clinical trials to confirm the safety and efficacy of therapies for major depressive disorder, addictions and cognitive improvement*. For more information, visit the company’s website at www.Cybin.com.
*Cybin makes no medical or treatment claims about its proposed products. Certain statements regarding psilocybin have not been evaluated by the Food and Drug Administration or other similar regulatory authorities, nor has the efficacy of psilocybin been confirmed by FDA-approved research. There is no assurance that psilocybin can be used to diagnose, treat, cure or prevent any disease or condition, and robust scientific research and clinical trials are needed. In addition, Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products are not intended to imply that such claims have been verified in clinical trials or that Cybin will be able to complete such trials. If Cybin is not able to obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on its performance and operations.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.